| Name | Title | Contact Details |
|---|---|---|
Angela Drysdale |
VP, Regulatory Affairs - Infectious Disease | Profile |
Ellen Chiniara |
General Counsel | Profile |
Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.
empowerins is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Evansville, IN. To find more information about empowerins, please visit www.empowerins.com
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
We provide emergency response, fall detection, activity monitoring, medication management, vitals monitoring and care traffic control for over 150,000 clients in all 50 states.
Advanced Products Inc is a Conway, AR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.